Browse
Submit Data
Databases
API
Help

Dataset Information

9 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Cancer therapy with vaccination using HLA-A02-restricted peptide from RNF43: a phase I study in patients with unresectable colorectal cancer

ABSTRACT: Interventions: Vaccination using epitope peptide from RNF43 Primary outcome(s): safety Study Design: Single arm Non-randomized

DISEASE(S): Unresectable Colorectal Cancer

PROVIDER: 2616205 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Phase I study of epitope peptides with UFT/UZEL for unresectable colorectal cancer

Project description:Interventions: Vaccination using epitope peptide from RNF43 and TOMM34 Primary outcome(s): safety Study Design: Single arm Non-randomized

| 2619184 | ecrin-mdr-crc

Immunotherapy Using HLA-A24-restricted Survivin-derived Peptide for Patients with Colorectal Cancer and Breast Cancer

Project description:Interventions: Survivin-2B peptide vaccination at a dose of 0.1mg every 2 weeks Survivin-2B peptide vaccination at a dose of 1.0mg every 2 weeks Survivin-2B peptide vaccination at a dose of 10mg every 2 weeks Primary outcome(s): Evaluation of adverse effect Study Design: Parallel Non-randomized

| 2616404 | ecrin-mdr-crc

Histocompatibility Leukocyte Antigen (HLA)-A*2402 Restricted Peptide Vaccine Therapy in Patients With Colorectal Cancer

Project description:The purpose of this study is to evaluate the safety and time to progression of HLA-A*2402 restricted epitope peptides RNF43, TOMM34, VEGFR1 and VEGFR2 emulsified with Montanide ISA 51 in combination with Tegafur/Uracil/Folinate chemotherapy.

| 2055342 | ecrin-mdr-crc

Cancer therapy with vaccination using HLA-A24-restricted peptide from RNF43:a phase I study in patients with unresectable colorectal cancer

Project description:Interventions: vaccination Primary outcome(s): safety Study Design: Single arm Non-randomized

| 2616206 | ecrin-mdr-crc

Cancer therapy with vaccination using HLA-A24-restricted peptide from TOMM34:a phase I study in patients with unresectable colorectal cancer

Project description:Interventions: vaccination Primary outcome(s): Safety Study Design: Single arm Non-randomized

| 2616285 | ecrin-mdr-crc

Inhibition of Tumor Growth and Metastasis by EMMPRIN Multiple Antigenic Peptide (MAP) Vaccination Is Mediated by Immune Modulation

Project description:We report here that a EMMPRINs-specific cancer peptide vaccination, where the peptide was modified and synthesied as a multiple antigenic peptide (MAP), significantly inhibited tumor growth and metastases. Specifically, we describe changes in the gene expression profile as assessed by RNAseq in tumors derived from mice implanted with the colon tumorigenic carcinoma (CT26 cells), and vaccinated with either a control scrambled multiple antigenic peptide (Scr-MAP) or with an epitope-specific EMMPRIN multiple antigenic peptide (designated 161-MAP).

2019-08-06 | GSE85440 | GEO

Cancer therapy with vaccination using HLA-A02 restricted peptide from human vascular endothelial growth factor receptor 2: a phase I study patients with unresectable colorectal cancer

Project description:Interventions: Vaccination Primary outcome(s): Safety Study Design: Single arm Non-randomized

| 2616207 | ecrin-mdr-crc

Cancer therapy with vaccination using HLA-A24-restricted peptide from human vascular endothelial growth factor receptor 2: a phase I study in patients with unresectable colorectal cancer

Project description:Interventions: Vaccination Primary outcome(s): Safety Study Design: Single arm Non-randomized

| 2616208 | ecrin-mdr-crc

Changes in gene expression in Pan02 tumors after TGFb-derived peptide vaccination

Project description:To investigate changes in the tumor microenvironment at a gene expression level induced by TGFb-derived peptide vaccination in a murine model of PDAC (Pan02)

2022-12-14 | GSE206764 | GEO

Phase II randomised clinical trial of personalized peptide vaccination in combination with Dai-kenchu-to for colorectal cancer patients resistant to standard therapies.

Project description:Interventions: arm1: The right peptides (up to 4 peptides) for vaccination to individual patients will be selected in consideration of the pre-existing host immunity assessed by the titers of anti-peptide IgG before vaccination, and subcutaneously injected with incomplete Freund’s adjuvant every week (3.0 mg/each peptide; 6 times/cycle). Dai-kenchu-to(5 g/time, 3 times/day) will be orally administered from the date of the first vaccination to the date of the sixth vaccination. If the patients want to continue the vaccination after completion of the first cycle of 6 vaccinations, the peptide vaccination will be allowed to continue (every 2-4 weeks). arm2: The right peptides (up to 4 peptides) for vaccination to individual patients will be selected in consideration of the pre-existing host immunity assessed by the titers of anti-peptide IgG before vaccination, and subcutaneously injected with incomplete Freund’s adjuvant every week (3.0 mg/each peptide; 6 times/cycle). If the patients want to continue the vaccination after completion of the first cycle of 6 vaccinations, the peptide vaccination will be allowed to continue (every 2-4 weeks). Primary outcome(s): Comparison of immune-enhancing effects (changes in anti-peptide IgG titers in plasma)between two groups. Study Design: Parallel Randomized

| 2623536 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data